# Effect of Anti-diabetic Drugs on Glycemic Variability

Study · id `cardio:ct-nct02925559` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02925559](<https://clinicaltrials.gov/study/NCT02925559>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02925559

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 135 participants.

## Technical summary

Registry record NCT02925559. Randomized; no masking; primary purpose treatment. Start 2016-10 (actual); primary completion 2018-02 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 135 participants (enrolled count; ClinicalTrials.gov record NCT02925559, source copy `cardio:ctgov-nct02925559-2020-03-04`, retrieved 2026-10-26)
- Started: 2016-10 (actual) (ClinicalTrials.gov record NCT02925559, source copy `cardio:ctgov-nct02925559-2020-03-04`, retrieved 2026-10-26)
- Primary completion: 2018-02 (actual) (ClinicalTrials.gov record NCT02925559, source copy `cardio:ctgov-nct02925559-2020-03-04`, retrieved 2026-10-26)
- Completion: 2019-01 (actual) (ClinicalTrials.gov record NCT02925559, source copy `cardio:ctgov-nct02925559-2020-03-04`, retrieved 2026-10-26)
- Countries: Brazil (ClinicalTrials.gov record NCT02925559, source copy `cardio:ctgov-nct02925559-2020-03-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02925559-2020-03-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of Anti-diabetic Drugs on Glycemic Variability
- Acronym: EFFORT
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Dapagliflozin
- Intervention (Drug): Gliclazide MR
- Lead sponsor: Centro de Diabetes Curitiba Ltda
- Lead sponsor class: OTHER
- Collaborator: AstraZeneca
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Dapagliflozin (`cardio:dapagliflozin`)
- Registry lists this organization as a collaborator: AstraZeneca (`cardio:astrazeneca`)

## Provenance

Content hash: 228e9af975eb82a9b4ed2ea1dbf72b2b41c69217e6ce2dbe7d5556022146001c
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
